Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Merck & Co, Inc; and Tesaro, a GSK company.

Community Practice Connections™: Ovarian Cancer Tumor Board: Leveraging Evolving Data Sets on PARP Inhibitors in Ovarian Cancer to Inform Treatment Decision-Making

Release Date: June 30, 2020
Expiration Date: June 30, 2021

Activity Overview

The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors has brought about a paradigm shift in the standard of care for patients with ovarian cancer. The efficacy of PARP inhibitors as maintenance therapy for patients with ovarian cancer has been established in clinical trials, leading to FDA approvals for this indication. Further research into the clinical properties of PARP inhibitors has expanded our understanding of both the mechanisms by which these agents target cancer cells and their use in additional lines of therapy.

This online activity features a series of video interviews with experts in ovarian cancer, in which they review the latest data regarding PARP inhibition therapy and implications for clinical practice in the context of patient case-based discussions. These experts will describe the factors that are considered in the clinical treatment decision-making process, including the integration of molecular and genomic testing, the consideration of emerging therapeutic approaches, such as combination regimens, and the mitigation and monitoring of potential adverse events associated with these therapies.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Merck & Co, Inc; and Tesaro, a GSK company.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward all medical oncologists, pathologists, radiation oncologists, and surgical oncologists who treat patients with ovarian cancer. Other oncology professionals who have an interest in the treatment of ovarian cancer, such as obstetricians/gynecologists, nurses, physician assistants, fellows, and residents, are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Analyze evidence related to molecular testing and its application in selection of therapy for patients with ovarian cancer.
  • Understand and apply key findings from clinical trials to specific clinical cases reflective of ovarian cancer cases encountered in clinical practice.
  • Evaluate emerging therapeutic approaches, including combination approaches, and their appropriateness for specific populations of patients with ovarian cancer.
  • Summarize strategies for recognition and management of adverse events associated with specific treatments for ovarian cancer.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Susana M. Campos, MD, MPH
Susana M. Campos, MD, MPH
Institute Physician
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Tesaro (clinical trial); Consultant: Clovis Oncology, Eisai Co, Mersana Therapeutics, Tesaro.

Don S. Dizon, MD, FACP, FASCO
Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Brown University
Director, Women’s Cancers
Lifespan Cancer Institute
Director, Medical Oncology
Rhode Island Hospital
Providence, RI

Disclosures: Grant Research Support: Bristol Myers Squibb, Kazia Therapeutics, Tesaro (institutional support for the FIRST trial); Consultant: data safety monitoring boards for AstraZeneca, Clovis Oncology, Regeneron Pharmaceuticals, Tesaro.

Kathleen Moore, MD
Kathleen Moore, MD
Associate Professor of Obstetrics and Gynecology
Jim and Christy Everest Endowed Chair in Cancer Research
The University of Oklahoma College of Medicine
Director of Clinical Research
Medical Director of the Clinical Trials Office
Stephenson Cancer Center
Oklahoma City, OK

Disclosures: Grant Research Support: Eli Lilly and Company, Merck & Co, PTC Therapeutics; Consultant: Aravive, AstraZeneca, Clovis Oncology, Eisai Co, Genentech/Roche, GSK/Tesaro, ImmunoGen, Merck & Co, Tarveda Therapeutics, Vavotar Life Sciences.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By